Edited by: Steve Bunk
J.L. Eron, S.L. Benoit, J. Jemsek, R.D. MacArthur, J. Santana, J.B. Quinn, D.R. Kuritzkes, M.A. Fallon, M. Rubin, "Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter," New England Journal of Medicine, 333:1662-9, 1995. (Cited in 120 publications through October 1997)
Comments by Joseph Jemsek, Nalle Clinic, Charlotte, N.C.
Among viruses that cause infectious disease, HIV is particularly adept at mutating to survive drug therapy. "That's the strongest argument for combination therapy, because you can corner the drug, as it were, and not allow it to mutate," notes Joseph Jemsek, director of clinical research at the Nalle Clinic in Charlotte, N.C. "The downside is, it's hard to take that many drugs forever."
DOUBLE COMBINATION: The Nalle Clinic's Joseph Jemsek was on the team that pioneered successful combination drug therapy for HIV.